At the time of writing, Xeris Biopharma Holdings Inc [XERS] stock is trading at $3.18, up 3.41%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The XERS shares have gain 5.65% over the last week, with a monthly amount glided 29.27%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 28, February 2024, Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024. In a post published today on Yahoo Finance, Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Wednesday, March 6, 2024. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to discuss the Company’s financial and operational results and provide full-year 2024 guidance.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on August 28, 2023, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $4.50. Previously, Jefferies started tracking the stock with Buy rating on October 21, 2022, and set its price target to $4. On April 28, 2022, Craig Hallum initiated with a Buy rating and assigned a price target of $6.50 on the stock. SVB Leerink started tracking the stock assigning a Outperform rating and suggested a price target of $6 on November 17, 2021. H.C. Wainwright initiated its recommendation with a Buy and recommended $4 as its price target on October 29, 2021. In a note dated February 18, 2020, Piper Sandler initiated an Overweight rating and provided a target price of $12 on this stock.
For the past year, the stock price of Xeris Biopharma Holdings Inc fluctuated between $1.13 and $3.26. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $3.18 at the most recent close of the market. An investor can expect a potential return of 104.4% based on the average XERS price forecast.
Analyzing the XERS fundamentals
According to Xeris Biopharma Holdings Inc [NASDAQ:XERS], the company’s sales were 152.67M for trailing twelve months, which represents an 62.56% jump. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at -0.32%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -4.49 and Total Capital is -0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 58.98.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.10 points at the first support level, and at 3.01 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.26, and for the 2nd resistance point, it is at 3.34.
Xeris Biopharma Holdings Inc [XERS] reported earnings per share of -$0.09 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.12/share, meaning a difference of $0.03 and a surprise factor of 25.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.14 per share as compared to estimates of -$0.13 per share, a difference of -$0.01 representing a surprise of -7.70%.
Ratios To Look Out For
It is important to note that Xeris Biopharma Holdings Inc [NASDAQ:XERS] has a current ratio of 1.82. As well, the Quick Ratio is 1.38, while the Cash Ratio is 0.53. Considering the valuation of this stock, the price to sales ratio is 2.88, the price to book ratio is 113.61.
Transactions by insiders
Recent insider trading involved SHERMAN JEFFREY W, Director, that happened on Nov 27 when 5400.0 shares were purchased., Pieper Steven completed a deal on Nov 20 to buy 28000.0 shares. Meanwhile, Director HALKUFF DAWN bought 5410.0 shares on Nov 20.
